Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: Results from a large retrospective study

American Journal of Gastroenterology

Volumn 110, Issue 7, 2015, Pages 1014-1021

  Mooiweer, E ^a   Van Der Meulen De Jong, A E ^b   Ponsioen, C Y ^c   Fidder, H H ^a   Siersema, P D ^a   Dekker, E ^c   Oldenburg, B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INDIGO CARMINE; METHYLENE BLUE; COLORING AGENT;

ARTICLE; CHROMOENDOSCOPY; COLON BIOPSY; COLON DISEASE; COLON DYSPLASIA; COLON TUMOR; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE SEVERITY; FIRST DEGREE RELATIVE; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; WHITE LIGHT ENDOSCOPY; ADULT; AGED; BIOPSY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC USE; EARLY DIAGNOSIS; FEMALE; HEALTH SURVEY; MALE; MASS SCREENING; MIDDLE AGED; PROCEDURES;

ADULT; AGED; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; COLORING AGENTS; CROHN DISEASE; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INDIGO CARMINE; INFLAMMATORY BOWEL DISEASES; MALE; MASS SCREENING; METHYLENE BLUE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES;

EID: 84936845929     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.63     Document Type: Article

References (21)

1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33.
2. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-9.
3. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev ( 2 ): 2006, CD000279.
4. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-60.
5. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51: V10-2.
6. van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol 2011; 109: 715-22.
7. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004; 60: 334-9.
8. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. Gastrointest Endosc 2007; 65: 998-1004.
9. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004; 53: 256-60.
10. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-Aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-8.
11. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-Targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008; 103: 2342-9.
12. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007; 132: 874-82.
13. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-89.
14. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-45.
15. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-To-back colonoscopies. Gastroenterology 1997; 112: 24-8.
16. Kiesslich R, Neurath MF. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 2004; 53: 165-7.
17. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated metaanalysis of population-based cohort studies. inflamm Bowel Dis 2013; 19: 789-99.
18. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-75.
19. van Schaik FD, ten Kate FJ, Offerhaus GJ, et al. Misclassifi cation of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. inflamm Bowel Dis 2011; 17: 1108-16.
20. Ullman T, Croog V, Harpaz N, et al. Progression of fl at low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-9.
21. Konijeti GG, Shrime MG, Ananthakrishnan AN, et al. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc 2013; 79: 455-65.